<DOC>
	<DOCNO>NCT02580370</DOCNO>
	<brief_summary>This safety efficacy study botulinum toxin type A subject lateral canthal line .</brief_summary>
	<brief_title>Safety Efficacy Botulinum Toxin Type A Topical Gel Lateral Canthal Lines</brief_title>
	<detailed_description />
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>In good general health Moderate severe lateral canthal line evaluate rest base investigator 's global assessment Moderate severe lateral canthal line evaluate rest base patient assessment severity Any neurological condition may place subject increase risk exposure botulinum toxin type A amyotrophic lateral sclerosis motor neuropathy , LambertEaton syndrome , myasthenia gravis Muscle weakness paralysis , particularly area receive study treatment Active skin disease irritation disrupt barrier treatment area Active eye disease irritation Eyelid ptosis , excessive dermatochalasis , deep dermal scarring , inability substantially effect LCL treat manually spread skin apart Use topical prescription retinoid product ( ) lateral canthal area 3 month prior Screening Undergone procedure may affect lateral canthal region 12 month prior Screening Treatment botulinum toxin type A lateral canthal area 6 month prior Screening 3 month anywhere else body</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>REALISE 1</keyword>
</DOC>